Alteogen Healthcare wins domestic distribution rights for LG Chem's anti-adhesion agent

Alteogen Healthcare, a subsidiary of Alteogen, said Wednesday that it has signed an exclusive distribution agreement with LG Chem for the exclusive distribution of Protescal, an anti-adhesion agent, in Korea.

Under the agreement, Alteogen Healthcare will exclusively distribute, sell, and market Protescal domestically.

Adhesion preventers are medical devices that prevent abnormal connections between organs or tissues after surgery. Their domestic market is about 150 billion won ($107 million).

According to Alteogen Healthcare, Protescal is highly biocompatible with hyaluronic acid, which has met the quality standards of the U.S. and European regulatory agencies and has a hemostatic effect due to the addition of alginate. Through multicenter clinical trials in Korea, it has been proven safe and effective in reducing adhesions during intrauterine surgery. It is widely used in gynecological surgery.

Alteogen Healthcare expects that its perineal laceration prevention agents, Tergase and Protescal, will synergize in gynecology. Alteogen Healthcare has sold and marketed Tergase, a recombinant hyaluronidase developed by Alteogen.

“In the anti-adhesion market, where many products are competing, we could conclude this agreement because LG Chem showed trust in our strategy and sales power, making the most of the synergy of Tergase and Protescal,” Alteogen Healthcare CEO Lee Jae-sang said. “We consider this the first step in strengthening our trust and partnership, and we will create the best results.”

Park Heui-sul, vice president of LG Chem Life Sciences Company, said, “We plan to continue expanding our business scope from infertility to women's healthcare in general. Starting with this partnership agreement, we will explore additional cooperation opportunities with Alteogen Healthcare.”

Meanwhile, Alteogen recently announced that its subsidiary ALTOS Biologics will merge with Alteogen Healthcare. Altheogen Healthcare, formed in February by combining Ceres F&D and LS Meditech, is being integrated into ALTOS Biologics nine months after its launch.

The merger is expected to be completed on Dec. 24. Ateogen said it aims to improve management efficiency and maximize resource utilization through organizational integration.